Physician profile
Nada Osman
NPI 1689986671
$2,794.59
in general payments reported to CMS, 2019-2025
27 companies · $1,140 in 2025
The $1,140 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $572 · 2020: $224 · 2023: $241 · 2024: $618 · 2025: $1,140.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,999.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,999.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $604.78 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Corcept Therapeutics | $351.91 | 2019-2025 | Korlym |
| Novo Nordisk INC | $255.74 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $210.56 | 2019-2025 | Jardiance, Tradjenta |
| Sanofi-Aventis U.S. LLC | $193.36 | 2019-2025 | |
| Abbott Laboratories | $162.34 | 2023-2025 | Freestyle Libre 3, Proclaim |
| Medtronic, INC. | $133.55 | 2024-2025 | Minimed 780g, Intellis Adaptivestim |
| Madrigal Pharmaceuticals | $88.41 | 2025 | Rezdiffra |
| Abbvie INC. | $82.65 | 2024-2025 | |
| Cequr Corporation | $80.94 | 2024-2025 | Cequr Simplicity |
| Shire North American Group INC | $80.48 | 2019 | |
| Amgen INC. | $66.94 | 2019-2024 | Evenity, Prolia |
| Medtronic Minimed, INC. | $60.60 | 2019 | |
| Xeris Pharmaceuticals, INC. | $58.01 | 2023-2025 | Gvoke Hypopen |
| Tandem Diabetes Care, INC. | $57.10 | 2024-2025 | T:Slim X2 Insulin Pump With Control-Iq |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Beta Bionics, INC. | $56.19 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Sequel Med Tech, LLC | $45.65 | 2025 | Twiist |
| Insulet Corporation | $35.12 | 2025 | Omnipod |
| Dexcom, INC. | $28.71 | 2025 | Dexcom G6 Transmitter |
| Astrazeneca Pharmaceuticals LP | $22.81 | 2019 | |
| Glaxosmithkline, LLC. | $22.19 | 2025 | Shingrix |
| Tolmar, INC. | $20.86 | 2025 | Jatenzo |
| Takeda Pharmaceuticals U.S.A., INC. | $18.07 | 2020 | |
| Kerecis Limited | $15.23 | 2019 | |
| Ibsa Pharma INC. | $14.66 | 2023 | Tirosint, Licart |
| Mannkind Corporation | $13.99 | 2020 | |
| Amneal Pharmaceuticals LLC | $13.74 | 2024 | Unithroid |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nada Osman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.